Table 1.
Frequency of teratoma formation after transplantation of multipotent adult germline stem cell (maGSC) SSC5 cells.
| Recipient strain | Site of transplantation | Number of transplanted cells | −CsA |
+CsA |
Duration of experiment (weeks) | ||
|---|---|---|---|---|---|---|---|
| Tumor at site of injection | Tumor at distant site | Tumor at site of injection | Tumor at distant site | ||||
| RAG2−/−γc−/− | Heart | 5 × 105 | 100% (8/8) | 75% (6/8) | 60% (3/5) | 0% (0/5) | 4 |
| RAG2−/− | Heart | 5 × 105 | 83% (5/6) | 33% (2/6) | 20% (1/5) | 0% (0/5) | 4 |
| C57BL/6 | Heart | 5 × 105 | 0% (0/7) | 0% (0/7) | 0% (0/6)a | 0% (0/6) | 1–4b |
| C57BL/6 | s.c. | 2 × 106 | 0% (0/9) | 0% (0/9) | 0% (0/9) | 0% (0/9) | 15 |
aIn our previous study, no tumors were observed after injection of 0.5–1 × 106 maGSC SSC5 cells into the hearts of six C57BL/6 mice treated with cyclosporine A (CsA) (10 mg/kg/day) at 4 weeks after transplantation (8).
bIn each group, three mice were sacrificed after 1 week and three (+CsA) or four (−CsA) mice after 2 weeks. In addition, three mice in each group were analyzed 3 days after transplantation and no tumors were found. Sham-operated C57BL/6 mice (n = 3 for −CsA and n = 3 for +CsA, per time point) received PBS instead of maGSCs. As expected, no tumors were observed at days 3, 7, and 14.